Movement Alert｜HBM HOLDINGS-B Falls 5.1% in Regular Trading, Revenue-Profit Divergence in Interim Results Continues to Weigh on Shares

Market Focus09-01

On September 1, HBM HOLDINGS-B fell 5.1% in regular trading to HKD 13.4, with turnover of HKD 19.69 million, extending a multi-session decline. The selloff reflects the market's continued negative reaction to the company's interim results released on August 27.

The company reported first-half revenue of USD 122 million, up 20.9% year-over-year, driven by molecule licensing and collaboration income rising to USD 113 million from USD 93.7 million. Research services and technology licensing fees also grew 23.8% to USD 9.4 million. However, net profit fell 11.16% to USD 64.85 million, as R&D costs surged from USD 17.96 million to USD 29.6 million and administrative expenses more than doubled from USD 7.36 million to USD 16.67 million, mainly due to increased headcount costs and litigation-related expenses. The persistent revenue-growth-without-profit-growth pattern has triggered consecutive sessions of selling pressure.

Within the Biotechnology sector, peers also traded lower: AKESO down 4.0%, INNOVENT BIO down 2.22%, BEONE MEDICINES down 1.3%, CANSINOBIO down 1.08%, while EVEREST MED bucked the trend with a 1.42% gain.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163287325?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 10:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163287325","market":"us","top_or_hot":-1,"title":"Movement Alert｜HBM HOLDINGS-B Falls 5.1% in Regular Trading, Revenue-Profit Divergence in Interim Results Continues to Weigh on Shares","media":"Market Focus","content":"<p><p>On September 1, HBM HOLDINGS-B fell 5.1% in regular trading to HKD 13.4, with turnover of HKD 19.69 million, extending a multi-session decline. The selloff reflects the market's continued negative reaction to the company's interim results released on August 27.</p><p>The company reported first-half revenue of USD 122 million, up 20.9% year-over-year, driven by molecule licensing and collaboration income rising to USD 113 million from USD 93.7 million. Research services and technology licensing fees also grew 23.8% to USD 9.4 million. However, net profit fell 11.16% to USD 64.85 million, as R&D costs surged from USD 17.96 million to USD 29.6 million and administrative expenses more than doubled from USD 7.36 million to USD 16.67 million, mainly due to increased headcount costs and litigation-related expenses. The persistent revenue-growth-without-profit-growth pattern has triggered consecutive sessions of selling pressure.</p><p>Within the Biotechnology sector, peers also traded lower: AKESO down 4.0%, INNOVENT BIO down 2.22%, BEONE MEDICINES down 1.3%, CANSINOBIO down 1.08%, while EVEREST MED bucked the trend with a 1.42% gain.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HBM HOLDINGS-B Falls 5.1% in Regular Trading, Revenue-Profit Divergence in Interim Results Continues to Weigh on Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HBM HOLDINGS-B Falls 5.1% in Regular Trading, Revenue-Profit Divergence in Interim Results Continues to Weigh on Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-01 10:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 1, HBM HOLDINGS-B fell 5.1% in regular trading to HKD 13.4, with turnover of HKD 19.69 million, extending a multi-session decline. The selloff reflects the market's continued negative reaction to the company's interim results released on August 27.</p><p>The company reported first-half revenue of USD 122 million, up 20.9% year-over-year, driven by molecule licensing and collaboration income rising to USD 113 million from USD 93.7 million. Research services and technology licensing fees also grew 23.8% to USD 9.4 million. However, net profit fell 11.16% to USD 64.85 million, as R&D costs surged from USD 17.96 million to USD 29.6 million and administrative expenses more than doubled from USD 7.36 million to USD 16.67 million, mainly due to increased headcount costs and litigation-related expenses. The persistent revenue-growth-without-profit-growth pattern has triggered consecutive sessions of selling pressure.</p><p>Within the Biotechnology sector, peers also traded lower: AKESO down 4.0%, INNOVENT BIO down 2.22%, BEONE MEDICINES down 1.3%, CANSINOBIO down 1.08%, while EVEREST MED bucked the trend with a 1.42% gain.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1163287325","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163287325","pubTimestamp":1788231494,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 1, HBM HOLDINGS-B fell 5.1% in regular trading to HKD 13.4, with turnover of HKD 19.69 million, extending a multi-session decline. The selloff reflects the market's continued negative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"变动警报|HBM HOLDINGS-B 常规交易下跌 5.1%，中期业绩收入利润差异继续拖累股价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"On September 1, HBM HOLDINGS-B fell 5.1% in regular trading to HKD 13.4, with turnover of HKD 19.69 million, extending a multi-session decline. The selloff reflects the market's continued negative reaction to the company's interim results released on August 27.The company reported first-half revenue of USD 122 million, up 20.9% year-over-year, driven by molecule licensing and collaboration income rising to USD 113 million from USD 93.7 million. Research services and technology licensing fees also grew 23.8% to USD 9.4 million. However, net profit fell 11.16% to USD 64.85 million, as R&D costs surged from USD 17.96 million to USD 29.6 million and administrative expenses more than doubled from USD 7.36 million to USD 16.67 million, mainly due to increased headcount costs and litigation-related expenses. The persistent revenue-growth-without-profit-growth pattern has triggered consecutive sessions of selling pressure.Within the Biotechnology sector, peers also traded lower: AKESO down 4.0%, INNOVENT BIO down 2.22%, BEONE MEDICINES down 1.3%, CANSINOBIO down 1.08%, while EVEREST MED bucked the trend with a 1.42% gain.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163287325","isCrawlerRequest":true}